Eventide is the faith-based asset manager that a lot of advisors whisper about because the flagship fund, the Eventide Gilead Fund, has actually beaten plenty of its secular peers over multi-year stretches. Which is strange, because Christian and values-based funds are typically the ones underperforming for ethical reasons.

So what's going on with Eventide, how does Gilead actually pick stocks, and is the outperformance sustainable?

Let's dig in.

The Eventide Philosophy

Eventide Asset Management was founded in 2008 in Boston by Finny Kuruvilla, a physician and investor with an evangelical Christian background. The firm manages several mutual funds under the Eventide brand, all of which apply what they call "Business 360" analysis, combining biblical ethics with financial fundamentals.

Eventide's approach is distinctive because it's not just about exclusions. Most faith-based funds focus heavily on what to avoid: alcohol, tobacco, gambling, etc. Eventide does those exclusions, but it also positively screens for companies they believe are making the world better. The firm uses the phrase "investing that makes the world rejoice" as their tagline.

This sounds soft and marketing-ey, but the actual implementation is rigorous. Eventide's analysts evaluate companies on customer impact, employee treatment, supply chain ethics, environmental stewardship, community impact, and product usefulness. Companies that score poorly across these dimensions don't make the portfolio even if they pass simple exclusion screens.

What ETGLX Holds

The Eventide Gilead Fund (ETGLX is the Class N share, ETNLX is the Class I share) is the firm's flagship growth fund. It's actively managed and generally holds 50 to 70 stocks with a small to mid-cap growth tilt.

Top holdings typically include companies in biotech, medical devices, software, and specialty industrials. Think names like Vertex Pharmaceuticals, Edwards Lifesciences, Entegris, Axon Enterprise, ResMed, Veeva Systems, ServiceNow, Monolithic Power Systems, Align Technology, and Halozyme Therapeutics. The portfolio is growth-tilted and often has significant exposure to healthcare innovation and specialized tech.

Sector breakdown is roughly: 30 to 38 percent healthcare (this is the distinctive feature), 25 to 32 percent technology, 12 to 16 percent industrials, 6 to 10 percent consumer discretionary, with smaller slices elsewhere. The healthcare overweight is striking and is partly philosophical: Eventide views medical innovation as one of the clearest examples of "investing that makes the world rejoice".

Expense Ratio: 1.27 Percent (Class N)

Here's the bad news. ETGLX Class N charges 1.27 percent per year. Class I (ETNLX) charges 1.02 percent but has a higher minimum investment. Either way, this is an expensive fund.

Why so much? Active management of a concentrated small-to-mid-cap portfolio is genuinely expensive. The Eventide analyst team does deep fundamental work on each holding. The Shariah and biblical screening adds overhead. And Eventide is a specialized firm without the scale to spread costs over trillions of dollars.

But 1.27 percent is a high bar. You need to outperform by more than that amount to justify holding this fund over a cheap index alternative. The interesting thing is that ETGLX has actually cleared that bar in several multi-year periods.

AUM: Around 4 to 5 Billion Dollars

Eventide Gilead is actually one of the largest faith-based mutual funds in the US. Assets are approximately 4 to 5 billion dollars across share classes as of early 2026. That's surprisingly large for a values-based actively managed fund, and it reflects both strong advisor adoption and consistently good performance over the past decade.

Performance: The Headline Number

This is where ETGLX stands out.

One-year total return: approximately 20 to 28 percent. Healthcare and specialty tech did well in 2025.

Three-year annualized: approximately 12 to 16 percent.

Five-year annualized: approximately 12 to 15 percent.

Ten-year annualized: approximately 13 to 16 percent. This is the important number. Over 10 years, ETGLX has kept up with or beaten the S&P 500 despite the expense ratio headwind and despite faith-based screening that excludes profitable sectors.

Since inception (July 2008): approximately 12 to 14 percent annualized. That's a very strong multi-decade record.

How is this possible? Partly because the Eventide team has been good at stock picking. Partly because the healthcare overweight has paid off during a period of strong biotech and medical device performance. Partly because the growth tilt benefited from a 15-year bull market in growth stocks.

The honest question: will this continue? Maybe not. Past performance is famously unreliable. The factors that helped ETGLX over the past decade (growth tilt, healthcare overweight, small-cap exposure) could become headwinds in a different market regime.

Morningstar and Peer Rankings

ETGLX has earned 4 and 5 star Morningstar ratings in its category (typically Mid-Cap Growth or Small-Cap Growth depending on period) and has outranked most peers in long-term tables. The fund has appeared on various "best of" lists for SRI and ESG funds for years.

Again, these are backward-looking measurements. They tell you the fund has been run well, but they don't guarantee future performance.

Concentration and Volatility

ETGLX is a concentrated portfolio, and with small-to-mid-cap growth tilt, it's meaningfully more volatile than large-cap index funds. During drawdowns, the fund can fall harder than the S&P 500.

In 2022, for example, ETGLX fell approximately 25 to 30 percent peak to trough, while the S&P 500 fell around 25 percent. The fund then recovered harder in 2023 and 2024. This is normal for growth-tilted funds: higher upside, higher downside, higher volatility overall.

If you can't stomach watching your fund drop 30 percent in a bear market, ETGLX might not be the right holding for you.

Minimum Investment

Class N (ETGLX) has a 1,000 dollar minimum to open. Class I (ETNLX) has a 100,000 dollar minimum. If your advisor has access to the Institutional class through a platform, you'll save 25 basis points per year, which is worth asking about.

Tax Efficiency

ETGLX is a mutual fund, so it distributes capital gains annually. With a concentrated, actively managed portfolio that trades more than a passive index, the distributions can be meaningful. If you're holding ETGLX in a taxable account, expect some tax drag from capital gains distributions.

In an IRA or 401(k), this doesn't matter. In a taxable brokerage, you might prefer an ETF structure for tax efficiency.

The Eventide Family

Eventide runs several funds beyond Gilead. The family includes:
- Eventide Dividend Opportunities (dividend-focused)
- Eventide Healthcare & Life Sciences (sector-focused on healthcare)
- Eventide Balanced (60/40 style)
- Eventide Limited Term Bond (fixed income)
- Eventide Multi-Asset Income (income-focused)

Each fund applies the same Eventide ethical framework but targets different asset classes or styles. For investors building a complete Eventide-based portfolio, the family covers most of what you'd need.

Faith Alignment Questions

Eventide is explicitly Christian in its approach, but the "Business 360" framework is broad enough that many investors of other faiths (and even secular ESG investors) find it acceptable. The exclusions overlap heavily with mainstream values-based investing: no alcohol, tobacco, gambling, pornography, abortion-related businesses, weapons manufacturers focused on indiscriminate weapons, and companies with demonstrable human rights violations.

Investors with specific theological requirements (observant Muslims, strict Catholics following USCCB guidelines, etc.) should still verify that Eventide's screening meets their particular standards. For most broadly-defined Christian investors, the framework works well.

Who ETGLX Makes Sense For

Christian investors who want active management and are willing to pay for it. Investors who believe fundamental stock picking can add value beyond cheap index exposure. People with longer time horizons who can tolerate higher volatility for potentially higher returns. Anyone who wants healthcare and innovation tilt combined with biblical values screening.

Who Should Look Elsewhere

Cost-sensitive investors who see 1.27 percent as too high regardless of performance. Investors in taxable accounts worried about capital gains distributions. Retirees who need lower volatility than a small-to-mid-cap growth fund provides. Anyone who prefers passive indexing for its own sake.

The Honest Outperformance Question

Here's the uncomfortable thing. ETGLX has outperformed, but many of its drivers (growth factor, small-cap factor, healthcare tilt) could mean-revert. Over the next decade, it's entirely possible that a broad halal index ETF like SPUS or a biblically responsible index like BIBL will match or beat ETGLX net of fees.

Active management premium tends to compress over time in efficient markets. Eventide has built a legitimate track record, but betting on continued outperformance is still a bet. Make that bet knowingly.

Bottom Line

ETGLX is a rare thing: a faith-based actively managed fund with a genuinely strong multi-year track record. The Eventide team has built credibility through consistent performance and thoughtful ethical framework.

The trade-offs are real: high expense ratio, growth concentration, tax inefficiency in taxable accounts, and no guarantee that past outperformance continues. But if you want a Christian-aligned, actively managed core holding and you can pay the fee, ETGLX has earned its spot on the shortlist.

Eventide Gilead Fund (ETGLX): Why It Outperforms (Sometimes)